RxDoctor Payments Data

Brittney Ward, APRN

Family · Danville, KYNPI 1649943697

Payments from drug & device makers

$1,980in general payments, 2019–2025

Across 31 payments — averaging $63.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$2K
  • Madrigal Pharmaceuticals$140
  • Verona Pharma, Inc.$62
  • Takeda Pharmaceuticals U.S.A., Inc.$58
  • QOL Medical, LLC$41
  • Johnson & Johnson$41
  • plus $100 from 6 others

What the payments were for

  • Travel & lodging$81941%
  • Food & beverage$1,16159%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,980 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$25,098
Medicare patients
51
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$29,298
JanuviaSitagliptin Phosphate20$27,916
OzempicSemaglutide17$21,810
JardianceEmpagliflozin32$19,535
EliquisApixaban12$12,854
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,251
LinzessLinaclotide21$11,835
XareltoRivaroxaban11$8,944
FarxigaDapagliflozin Propanediol15$8,709
MyrbetriqMirabegron12$5,183
Methenamine Hippurate21$1,800
Potassium Chloride79$1,229
Bumetanide14$1,106
Albuterol Sulfate HfaAlbuterol Sulfate20$833
Duloxetine Hcl54$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$17$29,29828 claims
Boehringer IngelheimJardiance$17$19,53532 claims
Johnson & JohnsonXarelto$41$8,94411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →